<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00544011</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000564118</org_study_id>
    <secondary_id>CHRB-Folfiri-III-Avastin</secondary_id>
    <secondary_id>INCA-RECF0432</secondary_id>
    <nct_id>NCT00544011</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>Phase II Study Evaluating the Association of Bevacizumab and Chemotherapy of the Type Modified FOLFIRI 3 in Patients With Metastatic Colorectal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Jean Minjoz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different&#xD;
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and&#xD;
      help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as&#xD;
      irinotecan, fluorouracil, and capecitabine, work in different ways to stop the growth of&#xD;
      tumor cells, either by killing the cells or by stopping them from dividing. Giving&#xD;
      bevacizumab together with combination chemotherapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well bevacizumab given together with combination&#xD;
      chemotherapy works in treating patients with metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate the objective response (complete and partial) rate in patients with metastatic&#xD;
           colorectal adenocarcinoma treated with bevacizumab and modified FOLFIRI 3 chemotherapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine progression-free and overall survival.&#xD;
&#xD;
        -  Determine the tolerance to this regimen.&#xD;
&#xD;
        -  Evaluate the resectability rate.&#xD;
&#xD;
        -  Evaluate biological markers predictive of the efficacy of this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive bevacizumab IV over 30-90 minutes on day 1, irinotecan hydrochloride IV over&#xD;
      90 minutes on days 1 and 3, and fluorouracil IV continuously over 46 hours on day 1.&#xD;
      Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      At 14 days after completing chemotherapy, patients with progressive or stable disease receive&#xD;
      maintenance therapy comprising bevacizumab and capecitabine.&#xD;
&#xD;
      Biological specimens are collected at baseline and before the fourth course of chemotherapy.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2007</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response (complete and partial) rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resectability rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers predictive of efficacy</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the colon or rectum&#xD;
&#xD;
               -  Previously untreated metastatic disease&#xD;
&#xD;
          -  Measurable disease by RECIST&#xD;
&#xD;
               -  Must not be located in a prior radiation field&#xD;
&#xD;
          -  No cerebral or meningeal metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Transaminases ≤ 2 times ULN (5 times ULN if liver metastases present)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2 times ULN (5 times ULN if liver metastases present)&#xD;
&#xD;
          -  Creatinine ≤ 130 μmol/L OR creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
          -  Proteinuria &lt; 2+ or urine protein ≤ 1 g/24 hours&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients of must use effective contraception&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Uncontrolled cardiac disease&#xD;
&#xD;
          -  Prior cerebral vascular accident&#xD;
&#xD;
          -  Uncontrolled arterial hypertension&#xD;
&#xD;
          -  Severe renal or hepatic insufficiency&#xD;
&#xD;
          -  Prior arteriopathy&#xD;
&#xD;
          -  Bleeding disorder or nonhealing wound&#xD;
&#xD;
          -  Coagulopathy&#xD;
&#xD;
          -  Other malignancy within the past 2 years except basal cell or squamous cell skin&#xD;
             cancer or curatively treated carcinoma of the cervix&#xD;
&#xD;
          -  Psychiatric disorder compromising comprehension or participation in the study&#xD;
&#xD;
          -  Intestinal occlusion or subocclusion not caused by medical therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior adjuvant bevacizumab or irinotecan hydrochloride&#xD;
&#xD;
          -  Concurrent aspirin (&gt; 325 mg/day) or therapeutic anticoagulants&#xD;
&#xD;
          -  Surgery in the past 28 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Borg, PhD</last_name>
    <affiliation>Hopital Jean Minjoz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Borg, PhD</last_name>
      <phone>33-381-668-705</phone>
      <email>christophe.borg@efs.sante.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>October 13, 2007</study_first_submitted>
  <study_first_submitted_qc>October 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2007</study_first_posted>
  <last_update_submitted>June 23, 2011</last_update_submitted>
  <last_update_submitted_qc>June 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2011</last_update_posted>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

